Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives

Felipe Ades, Dimitrios Zardavas, Ivana Bozovic-Spasojevic, Lina Pugliano, Debora Fumagalli, Evandro De Azambuja, Giuseppe Viale, Christos Sotiriou, Martine Piccart

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Gene expression profiling has reshaped our understanding of breast cancer by defining and characterizing four main intrinsic molecular subtypes: human epidermal growth factor receptor 2-enriched, basal-like, luminal A, and luminal B subtypes. Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A. It also exhibits worse prognosis and has a distinct profile of response to hormone therapy and chemotherapy. Although luminal cancers share similarities, the studies conducted in recent years using next-generation sequencing technology show that luminal A and B breast cancers should be perceived as distinct entities, with specific oncogenic drivers, rather than more proliferative varieties of luminal tumors. This review discusses the definition and molecular characterization of luminal B breast cancer and presents the available clinical evidence for chemotherapy and endocrine therapy patterns of response. It also provides an overview of ongoing research on molecularly targeted agents for this disease.

Original languageEnglish
Pages (from-to)2794-2803
Number of pages10
JournalJournal of Clinical Oncology
Volume32
Issue number25
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Breast Neoplasms
Hormones
Drug Therapy
Gene Expression Profiling
Neoplasms
Technology
Therapeutics
Research
human ERBB2 protein

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Ades, F., Zardavas, D., Bozovic-Spasojevic, I., Pugliano, L., Fumagalli, D., De Azambuja, E., ... Piccart, M. (2014). Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. Journal of Clinical Oncology, 32(25), 2794-2803. https://doi.org/10.1200/JCO.2013.54.1870

Luminal B breast cancer : Molecular characterization, clinical management, and future perspectives. / Ades, Felipe; Zardavas, Dimitrios; Bozovic-Spasojevic, Ivana; Pugliano, Lina; Fumagalli, Debora; De Azambuja, Evandro; Viale, Giuseppe; Sotiriou, Christos; Piccart, Martine.

In: Journal of Clinical Oncology, Vol. 32, No. 25, 01.09.2014, p. 2794-2803.

Research output: Contribution to journalArticle

Ades, F, Zardavas, D, Bozovic-Spasojevic, I, Pugliano, L, Fumagalli, D, De Azambuja, E, Viale, G, Sotiriou, C & Piccart, M 2014, 'Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives', Journal of Clinical Oncology, vol. 32, no. 25, pp. 2794-2803. https://doi.org/10.1200/JCO.2013.54.1870
Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, De Azambuja E et al. Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives. Journal of Clinical Oncology. 2014 Sep 1;32(25):2794-2803. https://doi.org/10.1200/JCO.2013.54.1870
Ades, Felipe ; Zardavas, Dimitrios ; Bozovic-Spasojevic, Ivana ; Pugliano, Lina ; Fumagalli, Debora ; De Azambuja, Evandro ; Viale, Giuseppe ; Sotiriou, Christos ; Piccart, Martine. / Luminal B breast cancer : Molecular characterization, clinical management, and future perspectives. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 25. pp. 2794-2803.
@article{c55fdae0534b4544a12f1750c91396f1,
title = "Luminal B breast cancer: Molecular characterization, clinical management, and future perspectives",
abstract = "Gene expression profiling has reshaped our understanding of breast cancer by defining and characterizing four main intrinsic molecular subtypes: human epidermal growth factor receptor 2-enriched, basal-like, luminal A, and luminal B subtypes. Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A. It also exhibits worse prognosis and has a distinct profile of response to hormone therapy and chemotherapy. Although luminal cancers share similarities, the studies conducted in recent years using next-generation sequencing technology show that luminal A and B breast cancers should be perceived as distinct entities, with specific oncogenic drivers, rather than more proliferative varieties of luminal tumors. This review discusses the definition and molecular characterization of luminal B breast cancer and presents the available clinical evidence for chemotherapy and endocrine therapy patterns of response. It also provides an overview of ongoing research on molecularly targeted agents for this disease.",
author = "Felipe Ades and Dimitrios Zardavas and Ivana Bozovic-Spasojevic and Lina Pugliano and Debora Fumagalli and {De Azambuja}, Evandro and Giuseppe Viale and Christos Sotiriou and Martine Piccart",
year = "2014",
month = "9",
day = "1",
doi = "10.1200/JCO.2013.54.1870",
language = "English",
volume = "32",
pages = "2794--2803",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",

}

TY - JOUR

T1 - Luminal B breast cancer

T2 - Molecular characterization, clinical management, and future perspectives

AU - Ades, Felipe

AU - Zardavas, Dimitrios

AU - Bozovic-Spasojevic, Ivana

AU - Pugliano, Lina

AU - Fumagalli, Debora

AU - De Azambuja, Evandro

AU - Viale, Giuseppe

AU - Sotiriou, Christos

AU - Piccart, Martine

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Gene expression profiling has reshaped our understanding of breast cancer by defining and characterizing four main intrinsic molecular subtypes: human epidermal growth factor receptor 2-enriched, basal-like, luminal A, and luminal B subtypes. Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A. It also exhibits worse prognosis and has a distinct profile of response to hormone therapy and chemotherapy. Although luminal cancers share similarities, the studies conducted in recent years using next-generation sequencing technology show that luminal A and B breast cancers should be perceived as distinct entities, with specific oncogenic drivers, rather than more proliferative varieties of luminal tumors. This review discusses the definition and molecular characterization of luminal B breast cancer and presents the available clinical evidence for chemotherapy and endocrine therapy patterns of response. It also provides an overview of ongoing research on molecularly targeted agents for this disease.

AB - Gene expression profiling has reshaped our understanding of breast cancer by defining and characterizing four main intrinsic molecular subtypes: human epidermal growth factor receptor 2-enriched, basal-like, luminal A, and luminal B subtypes. Luminal B breast cancer has been reported to have lower expression of hormone receptors, higher expression of proliferation markers, and higher histologic grade than luminal A. It also exhibits worse prognosis and has a distinct profile of response to hormone therapy and chemotherapy. Although luminal cancers share similarities, the studies conducted in recent years using next-generation sequencing technology show that luminal A and B breast cancers should be perceived as distinct entities, with specific oncogenic drivers, rather than more proliferative varieties of luminal tumors. This review discusses the definition and molecular characterization of luminal B breast cancer and presents the available clinical evidence for chemotherapy and endocrine therapy patterns of response. It also provides an overview of ongoing research on molecularly targeted agents for this disease.

UR - http://www.scopus.com/inward/record.url?scp=84906805668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906805668&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.54.1870

DO - 10.1200/JCO.2013.54.1870

M3 - Article

C2 - 25049332

AN - SCOPUS:84906805668

VL - 32

SP - 2794

EP - 2803

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 25

ER -